|Bid||31.65 x 100|
|Ask||35.03 x 300|
|Day's Range||31.55 - 32.54|
|52 Week Range||19.94 - 35.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.80|
The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday. Cellectis said it intended to make the three patents available for future licensing deals.
Categories: Yahoo FinanceGet free summary analysis Cellectis SA reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Cellectis SA – Regeneron Pharmaceuticals, Inc., Calithera Biosciences, Inc. and Novelion Therapeutics Inc. (REGN-US, CALA-US and NVLN-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)
Cellectis popped early Wednesday after it and Dow's Pfizer presented strong data for first in-human trials of a cancer therapy.
Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two Phase 1 studies in conjunction with Pfizer.
Stock Monitor: Cellectis Post Earnings Reporting LONDON, UK / ACCESSWIRE / November 30, 2017 / Active-Investors issued a free report on Viking Therapeutics, Inc. (NASDAQ: VKTX ), which is readily accessible ...
NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Cellectis SA (NASDAQ: CLLS ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 14, 2017 at 8:30 AM Eastern Time. ...
While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.